According to the results, high SETD4 expression was associated with poorer OS in ACC (Figure 2C) and KIRC patients (Figure 2D) and worse PFS in PRAD (Figure 2G), ACC (Figure 2H), LIHC (Figure 2I), and UVM patients (Figure 2J). Here, SETD4 is linked to adrenal cortex carcinoma.